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7ABBREVIATION
WHO - World Health Organisation
CKD - Chronic Kidney Disease
RBC - Red Blood Cells
EPO - Erythopoietin
KDIGO - Kidney disease Improving Global Outcome
TSAT - Transferrin saturation
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IV - Intra Venous
ESA - Erythropoiesis Stimulating Agents
USA - United States of America
DRIVE - Dialysis patient’s Response to IV iron with
Elevated ferritin level
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CIN - Chronic Interstitial Nephritis
ADPKD - Autosomal Dominant Polycystic Kidney
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8RVD - Renal Vascular Disease
HD - Hemo Dialysis
PD - Peritoneal Dialysis
NGO - Nongovernmental organisation
Govt. - Government
RIA - Radio Immuno Assay
TCA - Tricarboxilic acid
CNS - Central Nervous System
ANS - Autonomic Nervous System
PNS - Peripheral Nervous System
BMT-1 - Bivalent metal transporter-1
FP-1 - Ferroportin-1
IL-6 - Interleukin-6
PTH - Parathyroid hormone
DNA - Deoxy ribo nucleic acid
ACE - Angiotensin converting enzyme
GIT - Gastro intestinal tract
EPO-R – Erythropoietin Receptor
HIF - Hypoxia Inducible Factor
HMW - High molecular weight
DPO - Darbepoetin
ECG - Electro cardiogram
HCV - Hepatitis C virus
DOPPS – Dialysis outcomes and practice pattern study
9INTRODUCTION
Anemia is a common complication in chronic kidney disease
(CKD) patients. Anemia causes left ventricular hypertrophy and
congestive cardiac failure. It increases cardio vascular morbidity and
mortality1. It is also a non-traditional risk factor for progression of CKD2.
Anemia also causes fatigue, weakness, dizziness, breathlessness,
decreased exercise tolerance, decreased muscle strength, falls and
decreased quality of life3.  Iron  deficiency  is  one  of  the  major  causes  of
anemia  associated  with  CKD.  Iron  deficiency  may  be  absolute  or
functional deficiency. According to Kidney Disease Improving Global
Outcome (KDIGO) guidelines on anemia management in CKD a trial of
parenteral iron therapy or 1-3 month trial of oral iron therapy is suggested
if TSAT is < 30% and serum ferritin< 500 ng/ ml6. Following a black box
warning on Erythropoiesis stimulating agents (ESAs) regarding concerns
about malignancies and cerebro vascular events and also due to problems
in reimbursements there is a trend towards reduced usage of ESAs and
increased usage of IV iron in USA. Many centres in USA have  started
using higher iron dosage in spite of having ferritin levels  > 500 ng/ dl
when  TSAT  is  <  30%  based  on  Dialysis  patient’s  Response  to  IV  iron
with Elevated ferritin level (DRIVE) trial. According to DRIVE study
group intravenous iron therapy in dialylic patients with ferritin between
10
500- 1200 ng/ ml and TSAT < 25% caused significant improvement in
anemia and reduced ESA dosage need7. The intra venous (IV) iron usage
increased from 55% in 2010 to 77% in 2011 and stabilised at 66%-68%
in 2012 in USA. Higher threshold for ferritin (>800 ng/ml) is the norm in
many US centres.  In  25% of  dialysis  centres  2/3  of  patients  had  ferritin
level > 800 ng/ ml and 15% had ferritin 1200 ng/ ml8.   But  these
measures led to increased need for blood transfusions. Also there is
concern about iron overload.
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AIMS OF THE STUDY
1. To assess the Hb response to treatment with intravenous
iron in nondialytic CKD patients with anemia.
2. To assess whether the serum ferritin, serum iron, Total
iron binding capacity, transferrin saturation (calculated)
alone or in combination can predict the response to iron
therapy.
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REVIEW OF LITERATURE
Stages of CKD
CKD is defined as kidney damage or GFR <60 ml/ min/ 1.73 m2
presenting for > 3 months with implications on health9. Kidney damage is
diagnosed on the basis of presence of certain markers like persistent
proteinuria, active urine sediments, serum abnormalities, imaging studies
and histology10.
                      Table - 1  : STAGES OF CKD
STAGE DESCRIPTION
eGFR
(ml/min/1.73
m2)
PLAN OF
TREATMENT
1 Kidney damage with
normal or increased
GFR
? 90 Diagnosis and
treatment of
comorbidities
2 Kidney damage with
mildly decreased GFR
60-89 Estimate
progression
3 Kidney damage with
moderately decreased
GFR
30-59 Evaluate and
treat
complications
4 Kidney damage with
severely decreased GFR
15-29 Preparation for
RRT
5 ESRD <15 Dialysis or
transplantation
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           In India the incidence of ESRD is 151/ million population11.
Diabetes mellitus (DM 31.2%) forms the primary causative factor in
India just like the world over  followed by undetermined cause (16.4%),
CGN(13.8%), HT(12.8%), others(11.7%), CIN(7%), obstructive uropathy
(3.4%), ADPKD (2.5%), RVD(0.8%) and graft loss(0.3%)12.  Due  to  the
growing epidemic of DM the incidence of CKD & ESRD are increasing.
In India only 10-20% of ESRD patients get RRT in the form of renal
transplantation, HD or PD mainly through private sectors, NGOs and
Govt. Medical College Hospitals.
Complications of CKD
1. Cardio vascular disease.
2. Anemia.
3. Nervous system (CNS/ PNS/ ANS) abnormalities.
4. Mineral and bone disorder.
5. Metabolic abnormalities (hyper/hypoglycaemia, hyperlipidemia,
hypertriglyceridemia, protein catabolism)
6. Other endocrine abnormalities
- decreased libido, sexual function and
depression in men, reduced fertility in women
-  growth retardation in children
- Vitamin D  deficiency,
- hypertension
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RELATIONSHIP OF ANEMIA AND OTHER COMPLICATIONS.
Cardiovascular disease
Cardiac disease is major cause of morbidity and mortality in CKD
patients. Uremic toxins especially parathyroid hormones and anemia
cause cardiac muscle hypertrophy and cardiac failure.
Central nervous system disease
          Many of uremic symptoms like fatigue, weakness, dizziness,
cognitive impairment and decreased muscle strength initially thought of
due to CNS involvement are mainly due to anemia. Anemia also causes
impaired mobility and increased risks of falls.
Bone and mineral disease
         Marrow fibrosis caused by uremic toxins like parathyroid hormones
may aggravate anemia.
Anemia
         Anemia is defined as a state characterised by decrease red blood cell
and haemoglobin mass resulting in decreased oxygen carrying capacity
and decreased oxygen delivery to the tissues.  Anemia is diagnosed when
haemoglobin level less than 13 g/dl in men and less than 12 g/dl in
women6. The NICE guidelines advocate a higher Hb target (> 13.5 g/ dl
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in males). Renal anemia was defined as anemia occurring in patients with
GFR < 45ml/ min/ 1.73 m2 with DM and <30 ml/ min/ m2 without DM14.
The prevalence of anemia increases with progression of CKD. According
to  2nd annual report of Indian CKD Registry prevalence of anemia is
67.4% in CKD stage 1, 72.5% in stage 2, 83.5% in stage 3, 93.8% in
stage 4, 98.7% in stage 5. According to United States Renal Data System
(USRDS) the prevalence of anemia is 43% in CKD stages 1-2 and 57% in
CKD  stages  3-515.   In  contrast  prevalence  of  anemia  is  12%  to  14%  of
subjects at risk for kidney disease (Kidney Early Evaluation Programme
[KEEP]) and 5% to 6% in general population (National Health and
Nutrition Examination Survey [NHANES] 1999 to 2004)16.  Over half of
adults  with  CKD  stage  3  /  4  are  affected  with  anemia17. According to
predialysis survey on anemia management (PRESAM) 20% patients had
Hb > 12g/ dl and 2/3 had Hb < 11g/ dl18. In India prevalence of anemia is
33% in general population and 41% in CKD patients19.
Features of renal anemia
1. Anemia is rare in CKD stages 1-3(GFR > 30 ml/min/1.73 m2).
2. In diabetic CKD patients anemia starts early (eGFR <45
ml/min/1.73 m2)
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3. Anemia  is  severe  in  diabetic  CKD  patients,  younger  women  and
older men.
Figure – 1 :  Prevalence of anemia in CKD
Historical perspectives of anemia.
? 1825- First human to human blood transfusion was given in
London by James Blundell who transfused a man’s blood
into his wife for postpartum haemorrhage20.
? 1836- renal anemia was first described by Richard Bright21.
? 1906- Carnot and Deflandre discovered that serum from
rabbits (hemopoietins) when injected into other rabbits
stimulated RBC production.
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? 1948- Bonsdorff and Jalavisto named the hemopoietic factor
as erythropoietin.
? 1977- Purification of EPO was done.
? 1979- RIA of EPO.
? 1985-Cloning and expression of EPO gene.
? 1986-87- clinical trials of recombinant human EPO.
? Till 1980s blood transfusion and androgen were the
treatment modalities for anemia13.
Normal erythropoiesis
Figure - 2 : Normal Erythropoiesis
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             Erythropoiesis occurs mainly in bone marrow in adults. RBC
production starts with EPO independent maturation of multipotent stem
cells into colony forming unit – granulocyte, erythrocyte, monocyte,
macrophage (CFU-GEMM). CFU- GEMM develops into burst forming
unit Erythroid (BFU-E) which is the first cell to have EPO-R which again
develops into CFU- E from which erythroblasts, basophilic,
polychromatic, orthochromatic normoblasts, reticulocytes and mature
RBCs develop.
EPO
                                      Figure - 3  : Structure of EPO
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            EPO is a glycoprotein containing 165 aminoacids with a
molecular weight of 30 kDa. Kidney is the major site of EPO synthesis in
adults. 90% of EPO is secreted in the peritubular fibroblasts in the cortex
and outer medulla, the areas susceptible to hypoxia. Moderate hypoxia
stimulates additional EPO from liver, mainly hepatocytes and to some
extent from stellate or Ito cells. EPO is essential for maturation of RBCs.
EPO deficiency leads to neocytolysis of immature RBCs22.
EPO-R
          EPO-R is also a glycoprotein containing 484 amino acids. It is
synthesised in endoplasmic reticulum. It binds with tyrosine kinase and
Janus kinase-2. The entire complex associates with type 2 transferrin
receptor (TfR-2) for trafficking to cell membrane.
HIF
          Tissue hypoxia in the kidney provides the major erythropoietic
stimuli.
Hypoxia inducible factors are helix transcription factors consisting
O2 regulated ? subunits and constitutively expressed ? subunits. Under
normoxia, O2, Fe++ and ascorbic acid activate prolyl 4-hydroxylase
domain (PHD) proteins and degrade HIF.  Hypoxia and high
concentrations of TCA cycle intermediates inhibit PHD proteins allowing
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HIF-? to translocate to nucleus and activate hypoxia response elements
(HRE). HRE regulates numerous cellular processes like erythropoiesis,
angiogenesis and anaerobic metabolism. There are 3 HIFs. HIF-2 plays
an important role in erythropoiesis. HIF-1 is important in regulating
glycolysis. HIF-3 splice variants may actually inhibit transcription. HIF
proteins activate the transcription of PHD-2 and PHD-3 resulting in their
own degradation by negative feedback.
Iron
          Iron is essential for erythropoiesis. Total body iron is 50mg/kg.
65% of iron is in Hb; 10% in Mb, cytochromes and enzymes. Remainder
is in RES, liver and bone marrow. Differentiating erythroblasts need 20-
30 mg/ day of iron. Most of this iron is derived from recycling of
senescent RBCs.
          Daily intake of iron is 10- 20 mg/ day of which only 10% (Fe++) is
absorbed by enterocytes. Non heme iron presenting as Fe3+ needs to be
converted to Fe2+ by ferrireductase in conjunction with Vitamin C. Fe2+ is
transported by Divalent Metal Transporter - 1 (DMT-1) into enterocytes
which is delivered to circulation via ferroportin-1, oxidized to Fe3+ and
bound to transferrin.
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          Iron enters erythroblast when 2 transferrin molecules bind TfR-1
which then undergoes endocytosis into a clathrin coated sclerosome. Fe3+
is released and again reduced to Fe2+ by ferrireductase and exported to
cytoplasm via DMT-1. Cytosolic Iron enters mitochondria where
ferrochelatase causes its insertion into protoporphyrin IX to form heme.
Apotransferrin: TfR-1 complex is released into circulation for recycling.
Iron regulation
          1. When the iron storage is low there is upregulation of BMT-1,
FP-1, TfR-1 and increased absorption of iron from duodenal enterocytes.
          2. When iron is adequate hepcidin is secreted by liver which
combines with FP-1 in enterocytes, macrophages and hepatocytes and
degrades it thereby prevents iron absorption. Hepcidin is downregulated
by HIF in hypoxia, by soluble hemojuvelin in Iron deficiency, by EPO
during erythroblast formation.
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Figure – 4 :  Regulation of iron
HFE – human hemochromatosis protein 3. Inflammation and
infections through IL-6, bone morphogenic proteins and
lipopolysaccharides inhibit hepcidin expression, increase BMP-1
expression by macrophages and release of apolactoferrin and neutrophil
gelatinase- associated lipocalin(NGAL). These prevent release of iron
from RES thereby decrease its availability to iron dependent
microorganisms.
        4. Iron availability is regulated by iron response elements (IRE) in a
negative feedback mechanism.
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Other functions of iron
? Essential for cellular respiration and synthesis
? Converts harmless superoxide and hydrogen peroxide
(Fenton reaction)23 into toxic hydroxyl ions which causes
damage of adjacent macromolecules24.
? Can increase intracellular labile iron which causes lipid
peroxidation, DNA as well as membrane damage and
immunological disturbance25.
? Taken by iron dependant bacteria and precipitates infection.
Vitamin B12 and folic acid
           Vitamin B12 and folic acid are essential for many enzymatic
reactions in erythropoiesis.
Causes of anemia in CKD
1. EPO deficiency relative to the degree of anemia.
- Adaptation of kidney by attenuation of sodium channels
improves oxygenation in outer medulla thereby removes
hypoxic stimuli to EPO.
- Neutralisation of EPO by soluble EPO-R.
- Inactivation of EPO by desialysation due to uremia.
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- Blunting  of  action  of  EPO  in  marrow  by  absence  of
permissive factors like IL-3, calcitriol and CD4 cells and
presence of inhibitory factors like polyamines, ribonuclease
and PTH.
             EPO levels are normal or slightly increased in anemia of CKD.
Comparing  to  anemic  patients  with  CKD  anemic  patients  without  CKD
have 10-100 times EPO levels26(relative EPO deficiency).
2. Absolute and functional iron deficiency.
Blood loss, inhibition of iron absorption by hepcidin and  drugs,
poor intake due to anorexia and nausea are the main causes of Iron
deficiency. Even though iron deficiency is more common in CKD
patients on HD more than 50% of CKD stage 3 or 4 patients also have
Iron deficiency28. In addition to symptoms of anemia Iron deficiency
impairs cellular energy generation in skeletal and cardiac muscles,
oxygen storage in myoglobin, T cell proliferation and function, neuron
myelination and DNA synthesis29. Absolute iron deficiency is the
presence of low iron stores (serum ferritin < 100 ng/ml & TSAT <20%)64.
Functional iron deficiency occurs due to impaired release of iron from
RES.
1. Accelerated destruction of young and senescent RBCs.
2. Hemolysis during HD and also due to drugs.
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3. Deficiencies of vitamins B6, folic acid, B12 and L- carnitine.
4. Marrow fibrosis due to excessive PTH.
5. Chronic inflammation and infections.
6. ACE inhibitors.
7. Malignancy.
8. Pure red cell aplasia.
9. Hemoglobinopathies.
10.Malnutrition.
11.Hepcidin excess.
Inflammation increases hepcidin production from liver. CKD is
a chronic inflammatory state. IV iron may increase hepcidin
further and aggravate anemia30.
12.Aluminium toxicity, one of the major causes of renal anemia has
reduced significantly following improvements in HD and
reduced usage of citrates4,5.
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        Figure - 5 : Causes of Anemia in CKD
Diagnosis of anemia in CKD
Anemia is diagnosed when Hb level is below 13 g/dl in men and
below 12 g/dl in women6. Packed cell volume is not used to diagnose
anemia in CKD because of variations due to glucose concentration,
storage conditions or analysis techniques. There may be associated
thrombocytosis. Peripheral smear study may show normocytic
normochromic anemia to indicate anemia of chronic disease or
microcytic hypochromic anemia in case of Iron deficiency anemia and
macroytic anemia in case of folic acid,vitamin B12 deficiency and
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fragmented RBCs in hemolysis. Reticulocyte count may be increased in
case of hemolysis and decreased in case of marrow failure due to marrow
fibrosis. In macrocytosis serum B12 and RBC folate level should be
measured. Blood loss through GIT and hemolysis should be evaluated.
Iron indices
Iron indices show low serum ferritin, low serum Iron levels  and
low TSAT.
Serum ferritin
Serum ferritin level was taken as less than 100 ng/ml in non
dialytic patients and less than 200 ng/ml in dialytic patients. Now the
target has been increased to less than 500 ng/ml6. KDOQI doesn’t
recommend serum ferritin more than 500 ng/dl. This recommendation is
being disputed now. As ferritin is an acute phase reactant it can be
elevated in infection and inflammation but supply for erythropoiesis may
be low (low TSAT). In 47 non dialytic CKD patients the mean serum
ferritin level was 236 ng/dl but 46 patients didn’t have detectable bone
marrow Iron deposits60.
Serum iron
Serum iron levels may be modified by diurnal variation and food
intake.
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Reference values54
                              Males    - 65- 175 ?g/dl
                              Females -40- 150 ?g/dl
Total Iron binding capacity
Reference value
200-400 ?g/dl
Transferrin saturation(TSAT)
TSAT = serum Iron × 100 ÷ TIBC
         Target value – 30% - 40%
Initially iron deficiency was treated when TSAT is < 20%. Now
target has been increased to < 30%6.
Limitations of Iron indices
1. Acute phase reactant.
2. Diurnal variation
3. Variation due to food intake.
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Correlation of serum ferritin and TSAT with eGFR
According to NHANES III (1988- 2004) serum ferritin and TSAT
didn’t correlate with declining renal function in men. In women serum
ferritin increases with declining renal function while TSAT decreases
with eGFR decline61.
Other markers of anemia
1.  Reticulocyte Hb content (CHr).
2. Percentage of hypochromic red cells (PHRC).
3. Soluble transferrin receptor (sTfR).
4. Erythrocyte zinc protoporphyrin.
5. Hepcidin.
6. Bone marrow/ liver biopsy.
7. ESR/CRP.
Bone marrow iron stores
Bone marrow iron stores are the gold standard for diagnosis of iron
deficiency. Many have demonstrated iron deplete states in marrow of non
dialytic CKD patients. Silverberg has demonstrated 90% iron deplete
state in CKD patients60. Simona stancu observed 48% iron deplete state65
while  it  was  23%  in  Rahman’s  study66. Bone marrow iron stores could
not explain functional iron status in CKD patients. Simona stancu et al
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demonstrated that in 100 non dialytic CKD patients 1/3 of iron replete (52
iron replete patients) had > 1 g/dl Hb increase 1 month after 1 g Inj. iron
sucrose65.
          Both  PRBC  and  CFr  appear  imperfect  but  they  are  stable  and
accurate31.
EPO assays
          EPO assays are done in research laboratories only. Presence of
immunogenic EPO fragments27 are the major limiting factors for EPO
assays.
Hb variability
Hb variability is defined as fluctuation in Hb levels above or below
the original value within a short period even though  the mean value may
be within the target range32. The standard deviation of Hb in dialytic
CKD patients in US population is 1.1 to 1.3 g/ dl. It is believed to be due
to intermittent short nonbiologic burst of EPO especially in HD patients.
Causes may due to iron- EPO imbalance (EPO without iron) and vice
versa, infections, inflammation and blood loss. It is said to be a predictor
of mortality. To avoid this variation Hb should at least be measured
weekly once.
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Treatment of anemia in CKD
Target Hb
When Hb is below 10 g/dl CKD patients should be treated with
EPO after a loading dose of IV iron. Hb target should be between 11-12
g/dl. Target should not be more than 13 g/dl to prevent thrombosis related
events (stroke, angina, MI and vascular access failure). A higher dosage
of ESAs associated with higher Hb target is associated with increased
cardiovascular mortality33.
ESA administration
ESA is administered when Hb is less than 10 mg/ dl to keep the Hb
between 11-12 g/ dl.
ESA dosage
Epoetin- alfa or beta is started in the dosage of 20- 50 IU/ kg
weekly thrice , DPO with 0.45?g/kg SC/ IV weekly once dose or 0.75
?g/kg SC fortnightly and CERA with 0.6 ?g/kg SC/IV fortnightly in non
dialytic patients or 1.2 ?g/kg SC monthly once in CKD stage 5D. Women
and diabetic patient may need high ESA dosage.
Types of ESA
First generation ESAs
- Epoetin alfa
- Epoetin beta
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           Second generation ESAs
- Darbepoetin alfa- modified form of erythropoietin wih a
carbohydrate moiety which increases the half-life to 25 hours
by IV and 48 hours by SC injection45.  In  US  it  is  usually
given mainly in non dialytic patients46 as monthly injections.
        Third generation ESAs
- methoxy polyethylene glycol–epoetin beta (Mircera) has a
long half-life of 130 hours47. Half-life is same for IV as well
as SC forms48.
     Side effects of ESAs49
- HT
- Seizures
- Dialysis access clotting
ESA resistance
ESA resistance is defined as continued need for rHuEPO at doses
of > 300 IU/kg/week SC or > 400 – 450 IU/kg/week IV or darbepoetin at
a dose of 1.5 ?g/kg/week SC50.
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ESA resistance occurs in 10-20% of patients.
          Causes of ESA resistance
- Inflammation
- Iron deficiency
- Marrow fibrosis
- Hemolysis
- Nutritional deficiencies – folic acid, vitamin B6 ,
B12, L- carnitine
- Miscellaneous – pure red cell aplasia, aluminium,
ACEI/ARB.
Novel agents
          HIF prolyl- hydroxylase inhibitors, orally active prevent
degradation of HIF-?, thereby stimulate  EPO release. In experimental
studies it increases EPO levels 3 times more than normal51.
Management of iron deficiency
 Iron deficiency is treated when serum ferritin level is less than 500
ng/ ml and TSAT is less than 30%6. In dialytic patients parenteral iron
should be administered. In predialytic patients a 3 month trial of oral iron
or parenteral iron may be administered.
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Oral iron therapy
Ferrous sulphate, chloride, fumarate, gluconate and heme iron
polypeptide (HIP) are the oral iron preparations available. 200 mg of
elemental iron is administered daily.  Advantages are cheap, easy
administration and less systemic side effects. Disadvantages are GI side
effects, inability to administer in case of persistent vomiting and less
reliable absorption due to hepcidin and other medications especially in
dialytic CKD patients. Not effective in patients on EPO34. Ferric citrate
has in addition phosphate binding properties. In many trials oral Heme
Iron Polypeptide produce comparable Hb response63.
IV Iron therapy
Iron dextran, Iron sucrose, ferric gluconate, ferrumoxytol, ferric
carboxy maltose and Iron isomaltoside 1000 are the available IV Iron
formulations. Due to increased anaphylactic reactions Iron dextran
especially HMW is not  preferred now. Advantages of  IV Iron are utility
in dialytic patients, reliable absorption and compliance. It bypasses
absorption difficulties even in the presence of high hepcidin35.
Disadvantages are cost, need for saline and infusion sets and allergic
reactions. Other concerns are proteinuria due to proximal tubular injury,
peroxidation of lipids, infections, iron overload and hemosiderosis.
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Hemosiderosis is rare when serum ferritin level is less than 2000 ng/ ml.
In animal models iron administration may precipitate infections36,37,38,39.
IV Ferric carboxy maltose can rarely produce hypophosphstemia due to
its effect on FGF-23 especially in renal transplant recipients59.
Oral vs IV iron therapy
IV iron is indicated in dialytic patients. In non dialytic CKD
patients a trial of oral iron or IV iron is indicated. In non dialytic patients
2 doses of 510 mg IV Ferumoxytol given 5 ± 3 days gives good Hb
improvement in 35 days as against elemental oral iron 200 mg given for
21 days; Safety profile was good; can be given within a minute in fact
within 20 seconds40. IV iron therapy can reduce the need for higher EPO
dosages in dialytic patients and may delay the start of EPO
administration. Hb concentration and iron indices rise in short time
comparing to oral iron41,42,43. Less stable oral iron preparations like
ferrous sulphate can release iron rapidly and cause oxidative damage
while iron sucrose and ferric carboxy maltose are more stable.
Studies comparing Hb response to oral/IV iron therapies
1. Agarwal et al in 2006 compared oral (ferrous sulphate) vs IV iron
(sodium ferric gluconate) therapy in 75 patients and showed that Hb
response was more in IV iron therapy (0.4± 0.8 g/dl) than oral iron
(0.2± 0.9 g/dl)55.
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2. Qunibi et al in 2008 involving 188 patients over 8 weeks compared
oral (ferrous sulphate) vs IV iron therapy (ferric carboxy maltose) and
observed that Hb response to oral iron was 0.76±1.1 g/dl whereas to
that of IV iron was 1.16± 1.1 g/dl56.
3. Spinowitz et al in 2008 involving 188 patients compared oral iron
(ferrous fumarate) with IV iron (ferrumoxytol) observed that Hb
response to IV iron was 0.62± 1.02 g/dl and to oral iron was 0.13±
0.93 g/dl57.
4. Von wyck in 2005 compared 161 patients with oral ferrous sulphate
with IV iron sucrose and observed 0.7 g/dl Hb increase in IV iron
group and 0.4 g/dl Hb increase in ferrous sulphate group58.
Other studies assessing Hb response
1. Gabriel Mircescu et al from ‘Dr Carol Davila’ Teaching Hospital of
Nephrology, Bucharest, Romania treated 60 predialytic patients
with Hb less than 11 g/dl and serum ferritin levels between 20
ng/ml and <500 ng/ml with 200 mg monthly IV iron sucrose for 12
months (total dose 2400 mg). Mean pre-treatment Hb was 9.7 g/dl.
Mean Hb increase was 0.8 g/dl after 3 months and 1.3 g/dl after 1
year. Serum ferritin increased from 98 ng/ ml to 156 ng/ml (3
months) and 442.5 ng/ml (1 year). Serum iron increased from (73.9
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?g/dl) to 74.8 ?g/dl (3 months) and 442.5 ?g/dl (1 year). TSAT
increased from 21.6% to 24.9% (3 months) and 33.6% (1 year)52.
2. Silverberg et al administered 200 mg monthly IV iron sucrose for 5
months (total 1000 mg) and noted 1.9 vol% increase in Hct I month
after last iron dose53 in non dialytic patients from Switzerland.
Iron and hepatitis C infection
Hepcidin is synthesized by liver. Persistent hepatitis C infection
causes low hepcidin due to STAT3 activation which leads to
accumulation of iron in liver and augments liver injury (fibrosis, cirrhosis
and hepato cellular carcinoma). Iron removal by phlebotomy improves
liver function tests and liver histology.  Iron depletion also augments
HCV eradication by antiviral therapy and decreases the development of
hepato cellular carcinoma (HCC)44.
Adjuvant therapies
- Before  the  advent  of  ESAs  androgens  were  used  to  treat  anemia
which are not advocated now.
- Routine use of vitamins B, C,D, L-Carnitine  and pentoxyphylline
are not advocated now.
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Blood transfusions
            Blood transfusions should be avoided except in urgent indications
like blood loss, urgent preoperative corrections and unstable coronary
artery disease to avoid blood borne infections and also to prevent
sensitization in patients on renal transplant work up.
                 Management plan for anemia in CKD patients
Figure - 6 : Management protocol for CKD
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MATERIALS AND METHODS
Study design:
Prospective study.
Study Place  :
Kilpauk Medical College Hospital
Study Population
 INCLUSION CRITERIA:
?All CKD patients more than 18 years with
1. GFR < 60 ml/min/1.73 m2.
2. Hb < 10 g/dl.
 EXCLUSION CRITERIA:
? Patients with active infections/ active bleeding.
? Patients with recent myocardial infarction
? Patients with congestive cardiac failure.
? Patients with previous H/O allergic reactions to IV iron
sucrose.
? Patients on maintenance hemodialysis.
? Patients on oral iron therapy or erythropoietin therapy.
? Unwilling patients.
Sample size : 50
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Methodology:
           50 newly detected CKD patients more than 18 years who attended
nephrology outpatient department and admitted in medical and
nephrology wards in Govt. Kilpauk Medical College, Chennai were
included in this study after obtaining institutional ethical committee
permission from the period between December 2014- February 2015.
They were explained about the procedure and informed consent was
obtained. GIT bleeding was ruled out by doing stool for occult blood test.
Infections  were  ruled  out  by  doing  CBC,  X-  ray  chest,  urine  and  blood
C&S tests. 10 injections of iron sucrose were administered daily for 10
days in 100 ml NS over 1 hr. Pre-treatment Hb and Iron indices (serum
ferritin, serum iron, Total iron binding capacity and TSAT%(calculated)
were compared  with 1 month post treatment values. Three  patients
developed minor allergic reactions (rigors and itching) which were
treated with antihistamines. They were withdrawn from the study. 2
discontinued treatment due to personal reasons. Five patients didn’t return
for follow up study in spite of many reminders through mobile phones. At
the end 40 patients were assessed the Hb and iron indices response to IV
iron sucrose.
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Quantitative determination of serum iron.
         Principle – colorimetry
                  Reagent - ferrozine (spinreact)
Iron is dissociated from Transferrin- iron complex in weakly acid
medium. Liberated Fe 3+ is reduced to Fe2+ which gives Ferrozine, the
reagent used, a coloured complex.
Transferrin (Fe3+)2 + e-  ? 2 Fe2+  + transferrin
Fe2+? coloured complex
Total iron binding capacity
        Principle – saturation – precipitation
              Serum transferrin is saturated with an excess of Fe2+ and the
unbound portion is precipitated with magnesium carbonate. Total amount
of iron is then determined. Difference between total iron binding capacity
and initial serum iron yields unsaturated iron binding capacity.
Ferritin
        Principle – enzyme immune assay.
             Reagent – pathozyme ferritin (omega diagnostic)
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Specific anti-Ferritin antibodies are coated on to microtitration
wells. Test sera are applied. Then monoclonal anti – Ferritin labelled with
Horseadish peroxide enzyme is added. Ferritin if present is sandwitched
between Ab in the wells and Abs labelled with enzymes.
TSAT is calculated from serum Iron and TIBC
         TSAT = serum Iron ×100 ÷TIBC
eGFR was calculated using MDRD formula.
Conflict of interest: Nil
Financial grants: Nil
Statistical Analysis: was done using t test, paired t test, chi-square
test and ANOVA.
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RESULTS
ASSESSMENT OF Hb RESPONSE TO INTRAVENOUS IRON
THERAPY
Pre-Treatment & Post-Treatment Hb
Paired samples t-test
Sample 1 Hb_pre_
Hb(pre)
Sample 2 Hb_post_
Hb(post)
Sample 1 Sample 2
Sample size 40 40
Arithmetic mean 7.4500 8.2625
95% CI for the mean 7.0449 to 7.8551 7.8159 to 8.7091
Variance 1.6041 1.9496
Standard deviation 1.2665 1.3963
Standard error of the mean 0.2003 0.2208
Paired samples t-test
Mean difference 0.8125
Standard deviation 0.7858
95% CI 0.5612 to 1.0638
Test statistic t 6.539
Degrees of Freedom (DF) 39
Two-tailed probability P < 0.0001
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Mean pretreatment Hb is 7.45 g/dl while mean post treatment Hb is
8.26 g/dl.
Maximum pre-treatment Hb is 9.7 g/dl. Maximum post treatment Hb
is 10.8 g/ dl.
Minimum pre-treatment Hb is 5 g/ dl while minimum post
treatment Hb level is 5.1 g/ dl.
Median pre-treatment Hb level is 7.45 g/ dl while median post-
treatment Hb level is 8.3 g/ dl.
        One month after administration of 1000 mg Inj. Iron Sucrose there is
increase in Hb which is statistically significant (p < 0.0001). . Mean post-
treatment increase in Hb is 0.8 g/dl.
Description of dot and line diagram
Figure - 7 : Graphical representation of dot and line diagram.
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DOT AND LINE DIAGRAM
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Figure – 8 :  Dot and line diagram showing minimum, maximum and
median pre-treatment and post-treatment Hb values.
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DISTRIBUTION OF Hb INCREASE
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Figure – 9: Distribution of Hb increase
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AGE GROUP WISE Hb INCREASE
For statistical analysis patients are divided into 4 age groups.
Group 1 – age < 40 years
Group 2 – age 41-50 years
Group 3 – age 51- 60 years
Group 4 – age 61- 70 years
                  Mean age        – 55.825 years
                  Median age     – 58 years
                  Maximum age – 70 years
                  Minimum age – 19 years
95% Confidence Interval
for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound
Upper
Bound
Hb
diff.
1 4 1.175 .8655 .4328 -.202 2.552
2 7 .829 .7296 .2758 .154 1.503
3 12 .817 .9203 .2657 .232 1.401
4 17 .644 .8054 .1953 .230 1.058
Total 40 .781 .8182 .1294 .520 1.043
Table - 2
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There are 4 patients aged less than 40 years. Hb increase is more in
the age group < 40 years. Mean Hb increase in the age group < 40 years
is 1.175 g/dl.
         There are 7 patients in the age group between 41 – 50 years. 12
patients are in the age group between 51 – 60 years.  The mean Hb
increase in the age groups 41-50 years and 51-60 years come in between.
The mean Hb increases in the age groups 41—50 years is 0.83 g/dl and
mean Hb increase in the age group between 51 – 60 years is 0.82 g/dl.
         Patients aged more than 61 years form the major part of study
group. There are 17 patients in the age group more than 61 years. The
mean Hb increase is lower in the age group between 61-70 years. The
mean Hb increase in the age group between 61 years to 70 years is 0.644
g/dl.
49
Correlation of age & Hb response
Variable Y AGE
Variable X Hb_diff.
Hb diff.
Sample size 40
Correlation coefficient r -0.2053
Significance level P=0.2038
95% Confidence interval for r -0.4857 to 0.1135
          Age group wise mean Hb increase is statistically not significant (p-
0.2038).
Figure – 10 : Distribution of age group wise Hb increase
Scatter diagram
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The above scatter diagram clearly shows more number of patients
in the age group more than 61 years and less number of patients in the
age group less than 40 years. Age groups 41-50 years and 51-60 years
come in between.
             The scatter diagram also shows the Hb difference distribution.
Seven patients have reduced post treatment Hb level. Fifteen patients
have less than 1 g/dl increase in Hb level. Seventeen patients have 1-2
g/dl increase in Hb levels. One patient has 3 g/dl increase in Hb level.
             One patient in the age group less than 40 year has reduced post
treatment Hb level. One patient in the age group 41- 50 years, one patient
in the age group 51 – 60 years and four patients more than 61 years also
have reduced post treatment Hb levels. Two patients more than 61 years
have more than 0.5 g/dl decrease in Hb level.
              Two patients in the age group 41-50 years, six patients in the age
group 51-60 years and seven patients have upto 1 g/dl increase in Hb
levels.
             Three patients below 40 years have mean Hb increase of 1-2 g/dl.
Two patients in the age group 41-50 years, four patients in the age group
51-60 years and eight patients in the age group more than 61 years have
1-2 g/dl increase in Hb level.
             One patient in the age group 51-60 year has 3 g/dl increase in Hb
level.
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MEANS PLOTS
Figure - 11
               Group 1 - < 40 years
               Group 2 – 41-50 years
               Group 3 – 51-60 years
               Group 4 – 61- 70 years
       The above mean plot diagram shows highest mean Hb increase in age
group less than 40 years, lowest Hb increase in age group more than 61
years and intermediate Hb increase in age groups 41-60 years.
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SEX WISE Hb INCREASE
1- Male
2- Female
SEX N Mean Std. Deviation
Std. Error
Mean
Hb diff. 1 24 .725 .7450 .1521
2 16 .866 .9364 .2341
DIFF 1 24 6.17 6.790 1.386
2 16 2.76 18.897 4.724
Table - 3
       There are 24 males and 16 females. The mean Hb increase is more in
females comparing to males. The mean increase in Hb males is 0.725 g/dl
while in females it is 0.866 g/dl.
               Hb increase between males and females is statistically not
significant.
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CKD STAGEWISE Hb INCREASE
SERUM CREATININE
                                Mean – 4.825 mg/ dl
                               Median – 5.2 mg/ dl
                              Maximum – 6 mg/ dl
                              Minimum – 1.7 mg/ dl
95% Confidence
Interval for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound
Upper
Bound
Hb
diff.
3 1 1.700 . . . .
4 11 .791 .8080 .2436 .248 1.334
5 28 .745 .8321 .1573 .422 1.067
Total 40 .781 .8182 .1294 .520 1.043
DIFF 3 1 15.90 . . . .
4 11 6.69 5.553 1.674 2.96 10.42
5 28 3.67 14.934 2.822 -2.12 9.46
Total 40 4.80 12.938 2.046 .67 8.94
                             Table - 4 : CKD STAGES 3, 4 AND 5.
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eGFR
                             Mean         – 13.4275 ml/ min/ 1.73 m2
                             Median      – 11.45 ml/ min/ 1.73 m2
                             Maximum  – 32 ml/ min/ 1.73 m2
                              Minimum  – 7.8 ml/ min/ 1.73 m2
           There  is  only  one  patient  in  CKD stage  3.  Eleven  patients  are  in
CKD stage 4 and twenty two patients are in CKD stage 5.  Hb increase in
CKD stage 3 is 1.7 g/dl. Mean Hb increase is 0.8 g/dl and 0.74 g/dl in
CKD stages 4 and 5 respectively.
Minimum Maximum
Hb diff. 3 1.7 1.7
4 -.7 1.8
5 -.6 3.0
Total -.7 3.0
DIFF 3 16 16
4 -1 15
5 -59 19
Total -59 19
Table - 5
                 The minimum Hb increase is –0.7 g/dl in CKD stage 4 and -0.6
g/dl  in  CKD  stage  5.  The  maximum  Hb  increase  is  1.8  g  /  dl  in  CKD
stage 4 and 3 g/dl in CKD stage 5.
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MEANS PLOT DIAGRAM
Figure - 12 : The above graph showing more mean pre-treatment Hb
increase in early stages of CKD
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CORRELATION BETWEEN Hb INCREASE AND INCREASE IN
SERUM FERRITIN
Correlation
Variable Y Ferritin_Diff
Ferritin Diff
Variable X Hb_diff.
Hb diff.
Sample size 40
Correlation coefficient r 0.01421
Significance level P=0.9306
95% Confidence interval for r -0.2986 to 0.3243
           There is no statistically significant correlation between post
treatment increase in Hb and post treatment increase in serum ferritin.
Scatter diagram
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Figure – 13 :  The above scatter diagram showing more of ferritin
increase than decrease. Most of the patients have upto 100 ng/ ml
increase in serum ferritin levels.
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Correlation between Hb response  and TSAT% differencce
Correlation
Variable Y TSATDIFF
Variable X Hb_diff.
Hb diff.
Sample size 40
Correlation coefficient r 0.2458
Significance level P=0.1263
95% Confidence interval for r -0.07117 to 0.5177
          There is no statistically significant correlation between post
treatment increase in Hb and post treatment increase in TSAT%.
Scatter diagram
-1 0 1 2 3
-60
-50
-40
-30
-20
-10
0
10
20
Hb diff.
TS
A
TD
IF
F
Figure 14  The above scatter digram showing more of TSAT%
increase than decrease. Most patients have 10% - 20% increase in
TSAT% post-treatment.
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ASSESSMENT OF INDIVIDUAL IRON INDICES RISE
Assessment of Serum ferritin
Paired samples t-test
Sample 1 Ferritin_pre_
Sample 2 Ferritin_post
Ferritin post
Sample 1 Sample 2
Sample size 40 40
Arithmetic mean 311.0600 336.6200
95% CI for the mean 241.5705 to 380.5495 281.4788 to 391.7612
Variance 47210.6327 29727.1693
Standard deviation 217.2801 172.4157
Standard error of the mean 34.3550 27.2613
Paired samples t-test
Mean difference 25.5600
Standard deviation 142.3275
95% CI -19.9585 to 71.0785
Test statistic t 1.136
Degrees of Freedom (DF) 39
Two-tailed probability P = 0.2630
SERUM FERRITIN (ng/ml)
PRE-TREATMENT         POST- TREATMENT
Mean                                          311                                    336.6
Median                                      233.55                                318.4
Maximum                                  982.2                                 798.6
Minimum                                   68.8                                   82.6
             There is increase in mean serum ferritin levels of 25.56 ng/ dl
which is statistically insignificant (p = 0.2630).
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DOT AND LINE DIAGRAM
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Figure - 15 : The above diagram showing no significant ferritin
increase in spite of having increase in maximum post-treatment
ferritin value and median post-treatment ferritin value
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CORRELATION OF AGE & FERRITIN DIFFERENCE
Correlation
Variable Y AGE
Variable X Ferritin_Diff
Ferritin Diff
Sample size 40
Correlation coefficient r -0.3553
Significance level P=0.0245
95% Confidence interval for r -0.6004 to -0.04923
 There is significant  correlation (p= 0.0245) between age group
and post treatment ferritin rise.
SCATTER DIAGRAM
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Figure - 16 : The above scatter diagram showing upto 100 ng/ml
increase in post-treatment ferritin in many patients.
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SERUM IRON
Paired samples t-test
Sample 1 serum_Iron
serum Iron
Sample 2 Iron_post_
Iron(post)
Sample 1 Sample 2
Sample size 39 39
Arithmetic mean 120.5026 134.0795
95% CI for the mean 104.1450 to 136.8601 122.3607 to 145.7983
Variance 2546.3055 1306.8896
Standard deviation 50.4609 36.1509
Standard error of the mean 8.0802 5.7888
Paired samples t-test
Mean difference 13.5769
Standard deviation 38.8589
95% CI 0.9803 to 26.1735
Test statistic t 2.182
Degrees of Freedom (DF) 38
Two-tailed probability P = 0.0354
SERUM IRON (?g/dl)
Pre-treatment                        Post-treatment
Mean                                           120.5                            134
Median                                        118.35                          138
Maximum                                    283                               211.8
Minimum                                     36.3                              42
         There is post treatment increase in serum iron (13.57 ?g/dl) which
is statistically significant (p= 0.0354).
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DOT AND LINE DIAGRAM
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Figure - 17 : The above diagram showing distribution of pre and
post-treatment serum iron.
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TIBC
Paired samples t-test
Sample 1 TIBC_Pre_
TIBC(Pre)
Sample 2 TIBC_post_
TIBC(post)
Sample 1 Sample 2
Sample size 40 40
Arithmetic mean 435.3593 405.2555
95% CI for the mean 399.2723 to 471.4462 373.2151 to 437.2959
Variance 12732.1673 10036.8461
Standard deviation 112.8369 100.1841
Standard error of the mean 17.8411 15.8405
Paired samples t-test
Mean difference -30.1037
Standard deviation 73.0883
95% CI -53.4785 to -6.7290
Test statistic t -2.605
Degrees of Freedom (DF) 39
Two-tailed probability P = 0.0129
TIBC (?g/ dl)
                                   PRE-TREATMENT    POST-TREATMENT
Mean                                     435.3                             405.2
Median                                  412                                384.2
Maximum                              765.9                             652.8
Minimum                               217.2                             196.8
There is post treatment decrease in TIBC (30.1 ?g/ dl) which is
statistically significant (p= 0.0129).
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DOT AND LINE DIAGRAM
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Figure - 18 : The above diagram showing distribution of pre, post-
treatment TIBC.
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TSAT%
Paired samples t-test
Sample 1 TSAT%_pre_
TSAT%(pre)
Sample 2 TSAT%_post_
TSAT%(post)
Sample 1 Sample 2
Sample size 40 40
Arithmetic mean 29.1975 33.9665
95% CI for the mean 25.4102 to 32.9848 30.7912 to 37.1418
Variance 140.2331 98.5741
Standard deviation 11.8420 9.9285
Standard error of the mean 1.8724 1.5698
Paired samples t-test
Mean difference 4.7690
Standard deviation 13.4142
95% CI 0.4789 to 9.0591
Test statistic t 2.248
Degrees of Freedom (DF) 39
Two-tailed probability P = 0.0303
TSAT%
PRE-TREATMENT        POST- TREATMENT
Mean                                                   29.19 33.9
Median                                                28.7                          33.35
Maximum                                            76                            60.4
Minimum                                             10.8                         12.9
There is post treatment increase in TSAT% (4.769) which is
statistically significant (p= 0.0303).
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Correlation
Variable Y AGE
Variable X TSATDIFF
Sample size 40
Correlation coefficient r 0.05729
Significance level P=0.7255
95% Confidence interval for r -0.2588 to 0.3623
There is no statistically significant (p= 0.7255) age related TSAT
rise.
SCATTER DIAGRAM
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Figure - 19 : The above scatter diagram showing 10-20% increase in
post-treatment TSAT in many patients.
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Figure - 20
CORRELATION OF Hb RESPONSE AND PRE-TREATMENT
IRON INDICES
Correlation between pre-treatment serum ferritin and Hb response
To assess the correlation between pre-treatment serum ferritin and
Hb response patients were divided into three groups according to pre-
treatment serum ferritin levels.
1. Serum ferritin levels less than 200 ng/ml.
2. Serum ferritin levels between 200 – 500 ng/ml.
3. Serum ferritin levels more than 500 ng/ml
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Descriptive
Hb diff.
95% Confidence Interval
for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound
Upper
Bound
1 17 1.1059 .74117 .17976 .7248 1.4870
2 15 .7433 .86373 .22301 .2650 1.2216
3 8 .1625 .53436 .18892 -.2842 .6092
Total 40 .7813 .81820 .12937 .5196 1.0429
Table - 6
Descriptive
Hb diff.
Minimum Maximum
1 -.70 1.80
2 -.35 3.00
3 -.30 1.30
Total -.70 3.00
Table – 7
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ANOVA
Hb diff.
Sum of
Squares df
Mean
Square F Sig.
Between
Groups
4.876 2 2.438 4.248 .022
Within Groups 21.232 37 .574
Total 26.108 39
Table - 8
There are 17 patients with ferritin levels less than 200 ng/ml, 15
patients with ferritin levels between 200-500 ng/ml and 8 patients with
ferritin levels more than 500 ng/ ml.
Mean increase in Hb is 1.1 g/ dl, 0.74 g/ dl and 0.16 g/ dl in groups
1, 2 and 3.
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Means Plots
Figure - 21  : The above means plot diagram clearly shows the
increase in Hb response in patients with lower pre-treatment ferritin
levels.
Correlation between pretreatment serum iron and Hb response
For statistical purposes patients are divided into 2 groups
depending on pre-treatment serum iron levels.
Group 1 – pre-treatment serum iron below the reference value  (<
175 ?g/dl in males and < 150 ?g/dl in females).
Group 2 – pre-treatment serum ron above 175 ?g/dl in males and >
150 ?g/dl in females.
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Descriptives
Hb diff.
95% Confidence Interval
for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound Upper Bound
1 33 .7909 .72860 .12683 .5326 1.0493
2 7 .7357 1.23177 .46557 -.4035 1.8749
Total 40 .7812 .81820 .12937 .5196 1.0429
Table 9
Descriptives
Hb diff.
Minimum Maximum
1 -.70 1.80
2 -.35 3.00
Total -.70 3.00
Table  - 10
ANOVA
Hb diff.
Sum of
Squares df
Mean
Square F Sig.
Between Groups .018 1 .018 .026 .874
Within Groups 26.091 38 .687
Total 26.108 39
Table – 11
There  are  33  patients  within  the  reference  value  of  serum  Iron.  7
patients are having serum Iron above reference values.
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Means Plots
Figure - 22 : The above diagram clearly showing the inverse
relationship between pre-treatment serum iron and Hb response
Correlation between pre-treatment TIBC and Hb response
For statistical analysis patients are divided into 2 groups depending
upon the pre-treatment TIBC.
Group 1 – pre-treatment TIBC in the reference value  (200-400
?g/dl).
Group 2 – pre-treatment TIBC above 400 ?g/dl .
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Descriptives
Hb diff.
95% Confidence Interval
for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound Upper Bound
1 19 .5263 .77520 .17784 .1527 .9000
2 21 1.0119 .80435 .17552 .6458 1.3780
Total 40 .7812 .81820 .12937 .5196 1.0429
Table 12
Descriptives
Hb diff.
Minimum Maximum
1 -.70 1.60
2 -.35 3.00
Total -.70 3.00
Table – 13
ANOVA
Hb diff.
Sum of
Squares df
Mean
Square F Sig.
Between Groups 2.352 1 2.352 3.762 .060
Within Groups 23.756 38 .625
Total 26.108 39
Table – 14
There are 19 patients having TIBC within reference value and 21
patients having TIBC above reference value. Mean Hb increase in group
is less (0.52 g/ dl) than in group 2(1.01 g/dl).
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Means Plots
Figure - 23  :  The above means plot diagram showing direct
relationship between Hb response and pre-treatment TIBC.
Correlation between Hb response and pre-treatment TSAT
To assess the correlation between pre-treatment serum ferritin and
Hb response patients were divided into three groups according to pre-
treatment TSAT levels.
                           1. TSAT levels less than 20%
                           2. TSAT levels between 20% – 30%
  3. TSAT levels more than 30%
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Descriptives
Hb diff.
95% Confidence Interval
for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound Upper Bound
1 7 1.3429 .30472 .11518 1.0610 1.6247
2 17 1.1529 .45705 .11085 .9179 1.3879
3 16 .1406 .85969 .21492 -.3175 .5987
Total 40 .7813 .81820 .12937 .5196 1.0429
Table 16
Descriptives
Hb diff.
Minimum Maximum
1 .80 1.80
2 .30 1.80
3 -.70 3.00
Total -.70 3.00
Table - 17
7 patients have pre-treatment TSAT <20%, 17 patients have 20-
30% and 16 patients have pre-treatment TSAT > 30%. In patients with
pretreatment TSAT < 20% there is greater increase in post treatment Hb
(mean increase 1.34 g/dl) , patients with TSAT 20-30% have 1.15 g/dl
increase whereas in patients with pretreatment TSAT > 30% there  is not
much increase in post treatment HB (mean difference 0.14 g/dl).
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Hb diff.
Sum of Squares df Mean Square F Sig.
Between
Groups
11.123 2 5.561 13.731 .000
Within Groups 14.986 37 .405
Total 26.108 39
Table – 18 : ANOVA
Means Plots
Figure – 24 : There is inverse relationship between Hb response and
pre-treatment TSAT.
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Correlation of Hb response with pre-treatment serum ferritin and
TSAT levels
For statistical analysis patients are divided into 9 groups depending
upon pre-treatment serum ferritin and TSAT levels.
groups Pre-treatment serum
ferritin(ng/ml)
Pre-treatment TSAT
Group 1 < 200 <20%
Group 2 <500 <30%
Group 3 >500 >30%
Group 4 <200 <30%
Group 5 <200 >30
Group 6 <500 <20%
Group 7 <500 >30%
Group 8 >500 <20%
Group 9 >500 <30%
Table – 19
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Hb diff.
95% Confidence Interval
for Mean
N Mean
Std.
Deviation
Std.
Error
Lower
Bound Upper Bound
1 4 1.3750 .41932 .20966 .7078 2.0422
2 6 .9500 .35637 .14549 .5760 1.3240
3 5 -.1400 .20736 .09274 -.3975 .1175
4 9 1.4667 .18708 .06236 1.3229 1.6105
5 4 .0250 .78475 .39238 -1.2237 1.2737
6 2 1.3000 .14142 .10000 .0294 2.5706
7 7 .4071 1.16348 .43975 -.6689 1.4832
8 1 1.3000 . . . .
9 2 .3500 .07071 .05000 -.2853 .9853
Total 40 .7813 .81820 .12937 .5196 1.0429
Table - 20
Descriptives
Hb diff.
Minimum Maximum
1 .80 1.80
2 .60 1.50
3 -.30 .20
4 1.30 1.80
5 -.70 .80
6 1.20 1.40
7 -.35 3.00
8 1.30 1.30
9 .30 .40
Total -.70 3.00
Table - 21
79
ANOVA
Hb diff.
Sum of
Squares df
Mean
Square F Sig.
Between
Groups
14.499 8 1.812 4.840 .001
Within Groups 11.609 31 .374
Total 26.108 39
Table - 22
There are 4,6,5,9,4,2,7,1 and 2 patients in groups 1,2,3,4,5,6,7,8
and 9 respectively.
Mean increase in post-treatment Hb is 1.375 g/dl, 0.95 g/dl, - 0.14
g/  dl,  1.46  g/dl,  0.025  g/  dl,  1.3  g/dl,  0.4  g/  dl,  1.3  g/dl  and  0.35  g/  dl
respectively in groups 1,2,3,4,5,6,7,8 and 9 respectively.
There is greater increase in post-treatment Hb in patients with low
serum ferritin and low TSAT.
The Hb response decreases (mean Hb increase – 0. 14 g/ dl in Iron
replete patients (serum ferritin > 500 ng/ dl and TSAT > 30%).
When the pre-treatment TSAT is < 20 % the Hb response is good;
1.375 g/ dl with ferritin < 200 ng/ dl: 1.3 g/ dl with ferritin 200- 500 ng/
dl and > 500 ng/ dl.
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Means Plots
Figure - 25  : The diagram showing negative response in Iron replete
state and good response in patients with TSAT < 20 % and
intermediate response in other patient groups.
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DISCUSSION
Absolute and relative ron deficiency
           There is only one patient with absolute iron deficiency (serum
ferritin  <  100  ng/  dl  and  TSAT  <  20%).  But  there  are  20  patients  with
functional iron deficiency (serum ferritin < 500 ng/ml and TSAT < 30%).
4 patients (10%) have serum ferritin level less than 100 ng/dl and seven
(17.5%) patients have TSAT < 20%. According to NHANES III (1988-
96)  46%  of  women  and  19%  men  had  TSAT  <  20%.  47%  women  and
44% of men had ferritin < 100 ng/dl.
Hb response
          There is statistically significant increase in Hb level 1 month after 1
G Inj. iron sucrose IV in most of the patients.  Mean increase in Hb post
treatment is 0.81 g/dl. In many similar study groups the Hb response is
between  0.4  g/  dl  to  1.4  g/  dl  after  IV  iron  therapies.  In  similar  studies
Agarwal has observed 0.4 g/dl Hb response in 75 patients. Qunibi
observed 1.16 g/dl Hb response in 188 patients, Spinowitz 0.62 g/dl in
188 patients, Von wyk 0.7 g/dl in 188 patients, Anuradha 0.94 g/dl in 56
patients, Panesar 1.3 g/dl in 32 patients, Bennett 0.99 g/dl in 36 patients,
Atray 1.16 g in 22 patients and Post 1.4 g/dl in 5 patients.
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AGE GROUP
          The increase in Hb response is more in younger age group which is
statistically insignificant due to small number of patients in younger age
(<40 years). Majority of patients are from 61-70 years (17 numbers). This
may be due to more conservative non dialytic approach in older peoples
comparing to younger patients. Decreased response to IV iron in older
age group may be due to age related cytopenias.
SEX
           Males are expected to show higher Hb response than females due
to the influence of androgens over erythropoiesis. In our study females
fare slightly better than their male counterparts. This may be again due to
majority of patients being from older age group.
CKD STAGE
         Majority of patients are from CKD stages 4, 5 than CKD stage 3. In
general population CKD stage 3 are more than stage 4 or 5. But our study
was conducted in outpatient as well as in patients of tertiary health care
centre where the symptomatic CKD stage 4, 5 patients constitute the
majority of patients. As there is only one patient in CKD stage 3 we could
not assess the Hb response according to the CKD stages.
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           There is no statistically significant age, sex and CKD stage related
Hb response.
CORRELATION BETWEEN Hb RESPONSE AND FERRITIN
AND TSAT
           In our study there is no correlation between Hb response and
ferritin  and  TSAT  response.  In  a  similar  study  Silverberg  et  al  has
observed that there is no correlation between Hb response and ferritin and
TSAT response in CKD patients from Switzerland.
ASSESSMENT OF FERRITIN, IRON, TIBC AND TSAT
RESPONSES
           In our study serum ferritin increased from 311 ng/dl to 336.6 g/dl,
iron from 120.5 ?g/dl to 134 ?g/dl and TSAT from 29.19% to 33.9%.
TIBC decreased from 435.3 ?g/dl to 405.2 ?g/dl. In a similar study by
Gabriel Mircescu from Romania involving 60 patients serum ferritin
increased from 98 ng/ ml to 156 ng/ml a 3 months after 600 mg IV iron
Sucrose  and 442.5 ng/ml  1 year after 2400 mg IV iron Sucrose. Serum
iron increased from (73.9 ?g/dl) to 74.8 ?g/dl (3 months) and 442.5 ?g/dl
(1 year). TSAT increased from 21.6% to 24.9% (3 months) and 33.6% (1
year)52.
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           There is no statistically significant serum ferritin response. But
statistically significant age related ferritin response is present.
           There are statistically significant serum iron, TIBC and TSAT
responses present. But there is no age related response.
CORRELATION BETWEEN PRETREATMENT FERRITIN,
TSAT AND Hb RESPONSE
       When the TSAT is < 20% the Hb response is more irrespective of
serum ferritin levels. When serum ferritin is less than 200 ng/ dl the Hb
response is good if TSAT is < 30%. If the TSAT is > 30% there is no
significant Hb response in spite of having low serum ferritin levels (< 200
ng/ dl).When the serum ferritin is > 500 ng/ml or TSAT is >30% (Iron
replete state) there is negative Hb response. This is the basis for more
emphasis on TSAT rather than serum ferritin. This has been shown in the
2012 DOPPS study where more than half of dialytic patients have serum
ferritin >800ng/ml.
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LIMITATIONS OF THE STUDY
1. Small sample size.
2. No control group.
3. No long term follow up.
4. Hb is measured only once before and after treatment with
parenteral Iron therapy. Hb variability is not studied.
5. Gold standard bone marrow iron stores were not compared due to
ethical concerns.
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CONCLUSIONS
1. There is increase in Hb after one month of intravenous iron
therapy.
2. Pre-treatment transferrin saturation (TSAT) level < 20% is the
most important predictable factor to assess Hb response.
3. If TSAT is < 30%, Hb response is good even with high serum
ferritin level (>500 ng/dl).
4. Serum ferritin response is not statistically significant.
5. Iron, TIBC, TSAT responses are statistically significant
6. Response in Hb, ferritin and TSAT did not correlate with each
other.
7. There is a significant correlation between Hb response and pre-
treatment  ferritin and TSAT levels.
     8. There is no correlation between Hb response and pre-treatment
serum  iron and TIBC.
9. IV iron sucrose has very good safety profile except for a few minor
adverse effects.
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PROFORMA
NAME:                                                         AGE:                                  SEX:
ADDRESS                                                  MOBILE
D.O.A:                                         D.O.D                                       IP.NO:
HISTORY
Breathlessness         pedal edema               facial puffiness              easy fatiguability
anorexia                  Nausea/vomiting         Hematemesis                 malena
hematochezia          hemoptysis                  Hematuria                     Epistaxis
menorrhagia/scanty flow
Passing worms        Barefoot walking
Drugs
DM                          SHT                             CAD
GENERAL EXAMINATION
Conjunctiva                          tongue                              Hand skin crease
Nail changes                         pedal edema
 PR                                       BP                           Temp              RR
Weight
CVS                                      RS                                       ABDOMEN
INVESTIGATIONS
Hb
Pre-treatment                                                               post-treatment
Complete blood count
pretreatment                                                               post treatment
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Peripheral smear study
Blood sugar                                          urea                                     creatinine
eGFR (MDRD formula)
Na + K+
URINE albumin                                               deposits
URINE C&S                                                   BLOOD  C&S
Motion for occult blood
X-Ray chest                                ECG
ECHOcardiography
USG KUB
Serum ferritin
 Pretreatment                                                   post treatment
Serum iron
Pretreatment                                                    post treatment
Total iron binding capacity
Pretreatment                                                    post treatment
Transferrin saturation
Pretreatment                                                    post treatment
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MASTER CHART
SI.NO AGE SEX CREATININE(mg%)eGFR(ml/min/1.73m2 CKD STAGE Hb(pre)g/dl Hb(post)g/dl Hb diff.
1 57 1 5.8 10.8 5 9.7 9.4 -0.3
2 60 1 5.5 11.3 5 7.7 9 1.3
3 58 2 5.2 9 5 7 10 3
4 70 2 3 16.4 4 7.3 8.5 1.2
5 41 1 5.8 11.5 5 7.2 8.7 1.5
6 62 1 3.1 21.8 4 7.6 8.9 1.3
7 35 2 5.3 10 5 6 5.9 -0.1
8 65 2 5.8 7.8 5 7.3 7.9 0.6
9 48 1 4.2 16.2 4 8.2 9.5 1.3
10 60 1 5.1 12.4 5 7 7.8 0.8
11 55 1 4.3 16 4 8.4 8.1 -0.3
12 70 2 5.2 8.7 5 5 5.1 0.1
13 64 1 5.4 11.4 5 8 9.2 1.2
14 63 1 2.8 24.4 4 9 8.3 -0.7
15 66 2 1.7 32 3 8.3 10 1.7
16 52 1 2.8 25.4 4 7.8 8.4 0.6
17 53 1 6 10.5 5 7 7.2 0.2
18 68 2 5.2 8.7 5 5.2 6.5 1.3
19 19 2 5.2 11.3 5 6.2 7.8 1.6
20 65 2 5.6 8.1 5 6 5.7 -0.35
21 62 1 6 10.1 5 5 6.8 1.8
22 45 1 5.2 12.8 5 7.4 7.5 0.1
23 70 1 5.4 11.2 5 5.3 5.9 0.6
24 68 1 5.6 11.8 5 6.2 6.8 -0.6
25 68 1 4.8 12.9 5 8.5 8.6 0.1
26 44 2 3.9 13.3 5 9.3 9.6 0.3
27 21 2 3.5 17.5 4 7.5 9.3 1.8
28 55 1 5.3 20.8 4 8.1 8.3 0.2
29 68 1 4 15 4 9.1 10.5 1.4
30 70 1 5.8 10.3 5 6.7 7.5 0.8
31 58 1 3.5 19.2 4 9.2 10.7 1.5
32 52 1 3.8 17.9 4 9 9.4 0.4
33 62 2 5.2 8.9 5 7.2 8 0.8
34 56 2 5.6 8.6 5 8.2 9.2 1
35 50 1 5.2 12.5 5 8.2 9.6 1.4
36 34 1 5.4 13 5 6.2 7.6 1.4
37 47 2 5.6 8.7 5 8.2 8 -0.2
38 70 2 4.8 9.5 5 7.3 7 -0.3
39 52 2 5.4 8.8 5 6.1 7.5 1.4
40 50 1 6 10.6 5 9.4 10.8 1.4
Sex    1 - Male    2 - Female
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Ferritin(pre)ng/ml FERRITIN GROUP ferritin (post)ng/ml ferritin Diff  Iron(pre)?g/dl Iron group Iron(post)?g/dl
599 3 708 109 114 1 154
127.3 1 178 50.7 133.4 1 155
433.8 2 343.8 -90 283 2 139.4
225.4 2 252 26.6 57.4 1 78
125.5 1 155 29.5 38.4 1 42
138 1 243 105 142 1 183
575.9 3 612 35.9 123.2 1 142
418.9 2 453 34.1 150.2 2 168
136 1 175 39 78 1 112
374.8 2 354 -20.8 143.2 1 162
486 2 542 56 152 1 166
409.5 2 434 24.5 119.2 1 128
312.6 2 345 32.4 178 1 154
98.4 1 154 55.6 118 1 134.6
124.6 1 176.4 51.8 98.6 1 154
154.7 1 178 23.3 104.9 1 142
478 2 434 -44 184 2 138
504.5 3 289 -215.5 60.4 1 133,6
100.1 1 293 192.9 96.2 1 106.5
310.8 2 354 43.2 196.5 2 211.8
68.8 1 124.6 55.6 74.4 1 124.8
415 2 393.6 -21.4 118.7 1 123.4
368 2 452 84 134 1 178
77.4 1 82.6 5.2 103.3 1 132.8
202.4 2 186.2 -16.2 175 1 152.5
558 3 478.6 -79.4 138 1 152.4
121.2 1 437 315.8 159 2 123.8
641.5 3 412.6 -238.9 176.1 2 189.7
123 1 154.2 31.2 115 1 134.8
96 1 124 28 126.5 1 114.6
231.7 2 286.8 55.1 129 1 144.2
732 3 798.6 66.6 57.3 1 78.4
103 1 156.8 53.8 66 1 88.4
235.4 2 254 28.6 93.2 1 176.8
125 1 198.6 73.6 80.4 1 134.8
437 2 498.6 61.6 44.4 1 68.4
982.2 3 409.7 572.5 36.3 1 71.9
519.4 3 578.4 59 187.3 2 114.2
108.2 1 224 115.8 109.2 1 154
163.4 1 540.7 377.3 66.3 1 100.9
Ferritin group 1- < 200 ng/ml, 2- <500 ng/ml, 3- >500 ng/ml
Iron group     1- <175 ?g/dl in males, < 150 ?g/ml in females,
2- >175 ?g/dl in males, >150 ?g/dl    in females
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TIBC(Pre) TIBC group TIBC(post)TSAT%(pre)TSAT group TSAT%(post) TSAT DIFF(?g/ml) ferritin/TSAT group
333.9 1 298 34.1 3 51.6 17.5 3
626.4 2 512 21.2 2 30.2 9 4
765.9 2 416.4 36.9 3 33.4 -3.5 7
378.9 1 350 15.1 1 22.2 7.1 6
330.5 1 324 11.6 1 12.9 1.3 1
589 2 498 24.1 2 36.7 12.6 4
354.1 1 382 34.7 3 37.1 2.4 3
512 2 486 29.3 2 34.5 5.2 2
412 2 386 20.2 2 29 8.8 4
483.8 2 456 29.5 2 33.4 3.9 2
356 1 380 42.6 3 43.68 1.08 7
347.1 1 360 34.3 3 35.5 1.2 7
624.6 2 652.8 28.4 2 23.5 -4.9 2
390.8 1 362.6 30.1 3 37.12 7.02 5
412 2 386 23.9 2 39.8 15.9 4
340.8 1 312 30.7 3 45.5 14.8 5
534.6 2 496.2 34.4 3 27.8 -6.6 7
559.2 2 448.5 10.8 1 29.7 18.9 8
355.2 1 248.79 27 2 42 15 4
416.7 2 352 47 3 60.4 13.4 7
500.6 2 453.8 14.8 1 27.5 12.7 1
299.7 1 306.7 39 3 40 1 7
450 2 614.8 29.7 2 28.9 -0.8 2
282.9 1 265.9 36.5 3 49.9 13.4 5
497.1 2 464.8 35 3 32.8 -2.2 7
546.9 2 524.8 25.2 2 29 3.8 9
570 2 460.89 27.8 2 26.86 -0.94 4
546.4 2 624.48 31.2 3 30 -1.2 3
397.5 1 382.4 29 2 35.2 6.2 4
344.4 1 378 36 3 30.3 5.7 5
505 2 478.8 25.5 2 30.1 4.6 2
217.2 1 196.8 26.3 2 39.8 13.5 9
394.8 1 356.2 16.7 1 24.8 8.1 1
336.3 1 312.6 27.7 2 56.5 18.8 2
372.9 1 354.8 21.5 2 37.9 16.4 4
301.8 1 296.2 14.7 1 23 8.3 6
471.9 2 415.56 76 3 17.3 -58.7 3
373.2 1 342.9 50.1 3 33.3 -16.8 3
458.1 2 404.8 23.7 2 38 14.3 4
424.17 2 467.7 15.6 1 21.5 5.9 1
TIBC groups 1- < 400 ?g/dl,      2- > 400 ?g/dl
TSAT groups 1- < 20%,  2- < 30%  and 3 -> 30%
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KEY TO MASTER CHART
Ferritin & TSAT
groups
Pre-treatment serum
ferritin(ng/ml)
Pre-treatment
TSAT
Group 1 < 200 <20%
Group 2 <500 <30%
Group 3 >500 >30%
Group 4 <200 <30%
Group 5 <200 >30
Group 6 <500 <20%
Group 7 <500 >30%
Group 8 >500 <20%
Group 9 >500 <30%
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102
